Patients with HER-2+ breast carcinoma featuring TLS, that were treated with chemotherapy and/or HER-2 targeted therapy, showed a good treatment response to be attributed also to active antitumor immunity of TLS (Luen et al., 2017). The gene discussed is ERBB2; the disease is Tumor Lysis Syndrome.